RecruitingNot ApplicableNCT03953768

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

Prospective Non-randomized Single-arm Trial of Efferent Neuromodulation Immune and Gastrointestinal Systems by VNS in the Epilepsy Population


Sponsor

University of Louisville

Enrollment

30 participants

Start Date

Apr 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of action is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune and gastrointestinal systems. Concrete characterization of the peripheral effects of VNS in human gut microbiome and immune systems will: (1) elucidate peripheral mechanism of action of chronic VNS therapy, (2) identify peripheral preoperative biomarker of VNS efficacy, and (3) create a foundation for research investigating new GM and IM-related disease indications for VNS. The primary objective of this study is to characterize the pre- and post-operative oral and gut microbiome of patients implanted with vagal nerve stimulator (VNS) for epilepsy. Secondary objectives of this study include: (1) to characterize the pre-operative and post-operative immune profile of patients undergoing VNS implantation for epilepsy, (2) to elucidate whether oral and/or gut microbiota changes are related to VNS efficacy for epilepsy and (3) identification of a biomarker predicting VNS efficacy.


Eligibility

Min Age: 0 YearsMax Age: 60 Years

Inclusion Criteria3

  • Undergoing VNS implantation for the first time as a treatment for epilepsy and
  • Documented follow up with a Louisville-based neurologist in the past 1 year. If at the University of Utah or Baylor University documented ability to travel to their corresponding neurologist.
  • Documented ability to travel to Louisville for outpatient medical care. If at the University of Utah or Baylor University documented ability to travel to their facilities.

Exclusion Criteria10

  • Previous treatment with VNS (other than the one implanted for this study)
  • Current pregnancy (contraindication to surgery)
  • Active infection
  • History of cancer or treatment with chemotherapy
  • History of autoimmune disease: Patients who received high effect anticholinergic medication within 30 days of enrollment will be excluded, whereas moderate to low effect anticholinergic medication will be discussed with and decided by the PI.
  • If any high effect anticholinergic medication is started after enrollment, it will be the PI's decision to drop or postpone the corresponding visit or exclude the patient entirely.
  • Patients who received high effect corticosteroids within 30 days of enrollment will be excluded, whereas moderate to low effect corticosteroids will be discussed with and decided by the PI.
  • If any high effect corticosteroid is started after enrollment, it will be the PI's decision to drop or postpone the corresponding visit or exclude the patient entirely.
  • Treatment with antiarrhythmic or (heart) rate controlling medication,
  • Pre-existing cardiac arrhythmia or presence of cardiac pacemaker / defibrillator

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVagal nerve stimulation (VNS)

Implantation with vagal nerve stimulator for epilepsy


Locations(4)

Norton Healthcare

Louisville, Kentucky, United States

University of Louisville

Louisville, Kentucky, United States

Texas Children's Hospital

Houston, Texas, United States

Primary Children's Hospital/University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03953768


Related Trials